We report the synthesis of 3-phenylsulfonylmethyl cyclohexylaminobenzamides (class=""boldFont"">4) as CCR2 inhibitors for the potential treatment of inflammatory diseases. Several of the compounds display nanomolar binding affinity for CCR2. The in vitro structure-activity relationships of class=""boldFont"">4 are described, and are also reconciled with those from the related 2-phenylsulfonylmethyl series.